Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of aripiprazole in patients with major depressive disorder.

Trial Profile

A study of aripiprazole in patients with major depressive disorder.

Phase of Trial: Phase III

Latest Information Update: 24 Mar 2014

At a glance

  • Drugs Aripiprazole (Primary) ; Antidepressants
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 24 Mar 2014 A post hoc analysis of pooled data from 3 phase 3 studies, was published in Journal of Affective Disorders.
    • 06 Jun 2013 Based on results of this study, and CN138-163 and CN138-139, aripiprazole has received approval from Health Canada as adjunctive treatment of major depressive disorder, according to a Bristol-Myers Squibb media release.
    • 27 May 2010 Results from a pooled analysis (CN138-139, CN138-163 and CN138-165) were reported at the 163rd Annual Meeting of the American Psychiatric Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top